Expression Of MiR-5585-3p In Diffuse Large B-cell Lymphoma And Its Prognostic Significance

Purpose This study was designed to investigate the expression of miR-5585-3p in DLBCL and it’s relevance with clinical pathological features, prognostic significance in clinical practice.Methods Altered expression miRNAs were identified by microarray in an initial 12 DLBCL cases by using fold change≥1.5, P≤0.05 as cutoff value. MiR-5585-3p was one of them. The miR-5585-3p expression was confirmed by RT-qPCR in two different cohorts(12 DLBCL samples and 83 DLBCL samples),15 samples of reactive hyperplasia as controls. The clinical pathological data of patients were analyzed with the miR-5585-3p expression.Results1) The expression level of miR-5585-3p was significantly higher in DLBCL patients than in reactive hyperplasia samples (P< 0.001)2) The expression of miR-5585-3p in non-GCB was 2.4 times as much as in GCB subtypes (P=0.006)3) Positive correlation was observed between the miR-5585-3p expression level and IPI score (P=0.005)4) Kaplan-Meier analysis showed that higher expression level of miR-5585-3p was significantly associated with a poorer overall survival compared with lower expression miR-5585-3p DLBCL patients (Log-rank, P=0.049), however, GCB, there is no significant difference in OS between the GCB, non-GCB subtypes of DLBCL (Log-rank, P=0.390).5) Multivariable Cox regression revealed that the age>60 (P=0.010), IPI score 3-5(P=0.004), higher expression miR-5585-3p (P=0.014) were independent poor prognostic factors of DLBCL.Conclusions1) The expression levels of miR-5585-3p in DLBCL was higher than in reactive hyperplasia lymphoid nodes and it may be one of the novel biological markers of the DLBCL diagnosis.2) The expression levels of miR-5585-3p in DLBCL was higher in non-GCB subtype and it may be one of the novel biological markers to distinguish molecular subtypes of DLBCL and might be relative to the poor prognosis of DLBCL.